Results 51 to 60 of about 33,432 (282)

Effect of bromocriptine alginate nanocomposite (BANC) on a transgenic Drosophila model of Parkinson's disease

Disease Models & Mechanisms, 2016
The effect of bromocriptine, a dopamine agonist, administered in the form of bromocriptine alginate nanocomposite (BANC) was studied on Parkinson's disease (PD) model flies.
Y. Siddique, Wasi Khan, A. Fatima, Smita Jyoti, Saba Khanam, Falaq Naz, Rahul, Fahad Ali, B. Singh, A. Naqvi   +9 more
semanticscholar   +1 more source

The regulatory effect of bromocriptine on cardiac hypertrophy by prolactin and D2 receptor modulation

Clinical and Experimental Hypertension, 2020
Background Bromocriptine, a dopamine agonist, used for the treatment of hyperprolactinemia, type 2 diabetes, ovarian hyper-stimulation syndrome, has also effects on the cardiac remodeling process, but the mechanism of action is unknown.
Karla Aidee Aguayo-Cerón, Claudia Camelia Calzada-Mendoza, Enrique Méndez-Bolaina, Rodrigo Romero-Nava, María Esther Ocharan-Hernández   +4 more
doaj   +1 more source

Impact of ergot alkaloid and steroidal implant on whole-body protein turnover and expression of mTOR pathway proteins in muscle of cattle

Frontiers in Veterinary Science, 2023
IntroductionHolstein steers (n = 32) were used to determine if the ergot analog, bromocriptine decreases muscle protein synthesis through inhibitory action on the mTOR pathway via a direct effect on signal proteins, and if these negative effects can be ...
Taylor D. Ferguson, Caroline M. M. Loos, Eric S. Vanzant, Kristine L. Urschel, James L. Klotz, Kyle R. McLeod   +5 more
doaj   +1 more source

Parathyroid localization [PDF]

, 1986
Twenty-nine consecutive patients with suspected primary hyperparathyroidism were examined preoperatively using ultrasound, sonographically guided fine needle aspiration, and aspirate immunostaining for PTH.
Borisch, B., Gutekunst, R., Hafermann, W., Kiffner, E., Löhrs, U., Scriba, Peter Christian, Thies, E., Valesky, A.   +7 more
core   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Cannabinoid-deficient Benin republic hemp (Cannabis sativa L.) improves semen parameters by reducing prolactin and enhancing anti-oxidant status

BMC Complementary and Alternative Medicine, 2019
Background Nigerian Cannabis sativa (hemp) causes male gonadotoxicity by inducing hyperprolactinemia, down-regulation of hypothalamic-pituitary-testicular axis, and oxidative stress.
Abdullateef Isiaka Alagbonsi, Luqman Aribidesi Olayaki, Halimat Amin Abdulrahim, Thomson Sijuade Adetona, Gbemileke Tobiloba Akinyemi   +4 more
doaj   +1 more source

Inhibition of SKP2 Sensitizes Bromocriptine-Induced Apoptosis in Human Prolactinoma Cells

Cancer research and treatment : official journal of Korean Cancer Association, 2016
Purpose Prolactinoma (prolactin-secreting pituitary adenoma) is one of the most common estrogen-related functional pituitary tumors. As an agonist of the dopamine D2 receptor, bromocriptine is used widely to inhibit prolactinoma progression. On the other
Jinxiang Huang, Fenglin Zhang, Lei Jiang, G. Hu, Wei Sun, Chenran Zhang, Xuehua Ding   +6 more
semanticscholar   +1 more source

Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2015
In the article Gaziano et al, “Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects,” which published online October 12, 2012, and appeared in the October ...
L. Wilkins
semanticscholar   +1 more source

Matsupexole: A novel nonergot dopamine receptor agonist with sustained efficacy in a rat model of Parkinson's disease and limited off‐target activity

British Journal of Pharmacology, EarlyView.
Background and Purpose Dopamine receptor agonists, particularly targeting the dopamine D2L receptor (D2LR), have been used to treat Parkinson's disease (PD). However, valvular heart disease and somnolence, mainly caused by activating the serotonin 5‐HT2B receptor (5‐HT2BR) and dopamine D3 receptor (D3R), respectively, currently challenge their clinical
Takayuki Suzuki, Fumiki Oana, Masaki Oota, Yuma Handa, Osamu Kaminuma   +4 more
wiley   +1 more source

Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy

Clinical Research in Cardiology, 2015
BackgroundPeripartum cardiomyopathy (PPCM) is an idiopathic heart disease that develops in the last month of pregnancy and/or the first months following delivery in previously healthy women and may lead to acute heart failure.
A. Haghikia, E. Podewski, D. Berliner, K. Sonnenschein, D. Fischer, C. Angermann, M. Böhm, Philipp Röntgen, J. Bauersachs, D. Hilfiker-Kleiner   +9 more
semanticscholar   +1 more source